Stem cells injected twice may finally quench cancer survivors' dry mouth
NCT ID NCT07290946
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests whether two doses of stem cells, given four months apart, can improve saliva production and reduce dry mouth in people who had radiation for head and neck cancer or have Sjögren's disease. One hundred participants will receive either stem cells or a placebo. The goal is to see if repeated treatment works better than a single dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- allogeneic adipose-derived mesenchymal stem cells
- What this could lead to
- If it works, this could offer a new treatment for chronic dry mouth, improving saliva production and quality of life for cancer survivors.
- What could go wrong
- This is a phase 2 trial with only 100 participants. Previous stem cell studies showed limited success in restoring normal saliva flow, and repeated treatments may not work better. Risks include infection or immune reaction.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SJÖGREN'S SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental CAR-T injection aims to tame autoimmune diseases
- New MRI-Guided radiation aims to spare cancer patients from chronic dry mouth
- Engineered immune cells take aim at autoimmune diseases
- Engineered immune cells aim to tame childhood arthritis and lupus
- New cell therapy hopes to tame tough autoimmune diseases
- Experimental CAR t therapy takes on autoimmune diseases